World Clinical Drug
|
2024, 45(2): 176-180
• Article •
A case report on the use of pirfenidone in the treatment of immune checkpoint inhibitorassociated pneumonia caused by pabrizumab
Full
Jing LIN1, 2, Fahua SHI3, Xiaofei WANG1, *
Affiliations
- 1.Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Emergency revention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai 200025, China
- 2.Department of Pulmonary and Critical Care Medicine, the Second People's Hospital of Guizhou Province, Guiyang 550002, Guizhou Province, China
- 3.Department of Pulmonary and Critical Care Medicine, Qinghai Red Cross Hospital, Xining 810015, Qinghai Province, China
Published: 2024-02-10
doi: 10.13683/j.wph.2024.02.011
Outline
immune-related adverse events
/
checkpoint inhibitor pneumonitis
/
pirfenidone
林静, 施发花, 王晓斐.
吡非尼酮治疗帕博丽珠单抗导致的免疫检查点抑制剂相关肺炎1例.
世界临床药物,
2024
, 45
(2)
: 176
-180
.
DOI: 10.13683/j.wph.2024.02.011
Jing LIN, Fahua SHI, Xiaofei WANG.
A case report on the use of pirfenidone in the treatment of immune checkpoint inhibitorassociated pneumonia caused by pabrizumab[J].
World Clinical Drug,
2024
, 45
(2)
: 176
-180
.
DOI: 10.13683/j.wph.2024.02.011
Year 2024 volume 45 Issue 2
13
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.02.011
- Receive Date:2023-04-06
- Online Date:2026-11-18
- Published:2024-02-10